Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
AI specialist Exscientia signs drug discovery tie-up with Bayer
UK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking to use its platform to find new cardiovascular and cancer drugs.
Celgene backs out of $55M class action settlement on claims it blocked copycats to Revlimid, Thalomid
In an unusual move, Celgene has backed out of a $55 million settlement with patients and payers over allegations it illegally blocked competition to multiple myeloma meds Thalomid and Revlimid.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
Today, the U.
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE.
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1
Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and its skin cancer and alopecia drug BNZ-1.
Spain's Esteve sells a plant then buys one as it refocuses on specialty drugs
Spain's Esteve is picking up a German manufacturing site with a deal to buy Berlin-based Riemser from private equity firm Ardian.
Israeli researchers develop decoy molecule against deadly animal-to-human viruses
JERUSALEM, Jan.
New anti-cancer treatment developed by Hong Kong researchers significantly reduces tumour size
HONG KONG, Jan.
Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA (N-Nitrosodimethylamine) Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Scien
Mylan N.
Merck's Keytruda wins U.S. FDA approval for bladder cancer
(Reuters) - The U.
Boehringer Ingelheim's bet on Chinese CDMO market pays off with BeiGene's mAb approval
Germany-based Boehringer Ingelheim opened this €70 million biologics manufacturing facility in Shanghai to produce cell-based drugs targeted primarily at China.
Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture
Avacta Group plc (AIM.
370
371
372
373
374
375
376
377
378
